收费全文 | 21496篇 |
免费 | 1951篇 |
国内免费 | 434篇 |
耳鼻咽喉 | 106篇 |
儿科学 | 442篇 |
妇产科学 | 527篇 |
基础医学 | 1231篇 |
口腔科学 | 877篇 |
临床医学 | 2869篇 |
内科学 | 3254篇 |
皮肤病学 | 385篇 |
神经病学 | 1374篇 |
特种医学 | 260篇 |
外国民族医学 | 3篇 |
外科学 | 2095篇 |
综合类 | 1767篇 |
一般理论 | 3篇 |
预防医学 | 2014篇 |
眼科学 | 177篇 |
药学 | 3102篇 |
4篇 | |
中国医学 | 1945篇 |
肿瘤学 | 1446篇 |
2024年 | 87篇 |
2023年 | 570篇 |
2022年 | 831篇 |
2021年 | 1170篇 |
2020年 | 1050篇 |
2019年 | 1066篇 |
2018年 | 1031篇 |
2017年 | 969篇 |
2016年 | 839篇 |
2015年 | 833篇 |
2014年 | 1844篇 |
2013年 | 2356篇 |
2012年 | 1226篇 |
2011年 | 1202篇 |
2010年 | 949篇 |
2009年 | 933篇 |
2008年 | 1003篇 |
2007年 | 895篇 |
2006年 | 821篇 |
2005年 | 678篇 |
2004年 | 598篇 |
2003年 | 450篇 |
2002年 | 394篇 |
2001年 | 302篇 |
2000年 | 235篇 |
1999年 | 205篇 |
1998年 | 173篇 |
1997年 | 169篇 |
1996年 | 124篇 |
1995年 | 91篇 |
1994年 | 117篇 |
1993年 | 79篇 |
1992年 | 73篇 |
1991年 | 61篇 |
1990年 | 57篇 |
1989年 | 76篇 |
1988年 | 53篇 |
1987年 | 46篇 |
1986年 | 23篇 |
1985年 | 40篇 |
1984年 | 33篇 |
1983年 | 25篇 |
1982年 | 18篇 |
1981年 | 17篇 |
1980年 | 12篇 |
1979年 | 18篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1973年 | 7篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献